Compare Biogen Inc (BIIB) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Trade Desk Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Trade Desk Inc trades at $13.46 (market cap $6.37B). The key difference: Biogen Inc is far larger — about 4.7× Trade Desk Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | TTD | |
|---|---|---|
Market Cap | $30.13B | $6.37B |
Sector | Health | Technology |
52-Week High | $216.63 | $55.36 |
52-Week Low | $128.93 | $13.39 |
Enterprise Value | $37.20B | $5.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
The Trade Desk (TTD) trades at $13.66, down 90% from its 2024 peak, with bearish technical signals and recent earnings misses. Revenue growth slowed to 3% in Q2 2026, and Q3 guidance projects a 12% decline. Despite strong profitability margins (net margin 13.6%), the stock faces execution challenges and advertiser pressure. Analyst sentiment is mixed with a $13.87 price target, while institutional selling and downgrades reflect mounting concerns.
Outlook remains cautious amid weak guidance and competitive threats, though current valuations (P/E 16.1) may attract value investors. Key risks include persistent revenue declines and market share erosion. Recovery hinges on stabilizing advertiser relationships and reversing recent execution gaps.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
